Our pipeline
Target/Product
Research
Preclinical
Phase 1
Phase 2
Phase 3
Upcoming Milestones
Porcupine Inhibitor
(RXC004)
Initiate Combination arm – 2022
Topline data – H1 2023
RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as…
Initiate Combination arm – 2022
Topline data – H1 2023
RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as…
ROCK2
Selective Inhibitor
(RXC007)
Initiate Phase 2a – 2022
RXC007 is an orally available, highly selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signalling pathway, believed to be central to fibrosis. ROCK2 is therefore an important emerging drug target and RXC007 has the potential to….
GI-targeted
ROCK Inhibitor
(RXC008)
Our GI-targeted ROCK inhibitor is a first-in-class programme designed to treat Crohn’s Disease-associated fibrosis. Up to 50% of patients with Crohn’s disease can develop significant fibrosis and stricture formation within 10 years after diagnosis. The current management of fibrotic strictures of the gastrointestinal (GI) tract is primarily surgical…
DDR Inhibitor
(Discoidin Domain Receptor)
Progress programmes – target of 3 IND’s by 2025
- RXC008 IND submission – end 2023
Discoidin domain receptors (DDRs) were discovered in the 1990’s but more recently they have gained traction as new therapeutic targets with potential to treat multiple fibrotic conditions. DDRs are receptor tyrosine kinases containing a discoidin homology domain in their extracellular region, which bind to collagen….
Research Targets
(Wholly-owned)
Porcupine Inhibitor
(RXC006/AZD5055)
Licensed to AstraZeneca
In August 2020, Redx Pharma signed a significant out licensing agreement for our porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF)…
Pan-RAF Inhibitor
(JZP815)
Sold to Jazz Pharmaceuticals
Pan-RAF inhibitor sold to Jazz Pharmaceuticals, Pan-RAF inhibitor programme aims to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs. Mutations leading to uncontrolled signalling via the RAS-RAF-MAPK pathway are seen in over one third of all cancers. The RAF kinases (A-RAF, B-RAF and C-RAF) are an integral part of this pathway, with B-RAF mutations commonly seen…
MAPK Pathway
(undisclosed target)
Progress towards IND
In September 2020, Redx signed a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets on the Ras/Raf/MAP kinase (MAPK) pathway. Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission…
DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase
